1. Corneal crosslinking in keratoconus management
- Author
-
L. Trinh, S. Kallel, Sami Saad, I. Goemaere, Vincent Borderie, Nacim Bouheraoua, Rana Saad, L. Jouve, CIC 1423 DHU Sight Restore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de la Vision, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CCSD, Accord Elsevier, and Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,Keratoconus ,Corneal Infection ,Ultraviolet Rays ,Riboflavin ,[SDV]Life Sciences [q-bio] ,03 medical and health sciences ,0302 clinical medicine ,Ophthalmology ,Cornea ,Humans ,Medicine ,ComputingMilieux_MISCELLANEOUS ,Photosensitizing Agents ,business.industry ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Cross-Linking Reagents ,medicine.anatomical_structure ,Photochemotherapy ,Clinical evidence ,030221 ophthalmology & optometry ,Ultraviolet Therapy ,Collagen ,business ,Vitamin b2 - Abstract
Since two decades, corneal crosslinking (CXL) has been proposed as the sole therapeutic option to halt progression of keratoconus or other ectatic diseases. CXL aims at stiffening the cornea using a combination of ultraviolet-A light and a chromophore (vitamin B2, riboflavin), and has been proposed in various indications, from progressive ectatic diseases to corneal infection. Despite being in clinical use for many years, many controversies and discrepancies exist towards CXL procedure and its exact role is still under debate. We report an up-to-date review of the state of the art of CXL and describe the basic principles, the different existing CXL techniques reporting basic and clinical evidence, as well as the new perspectives and the possible future developments of the procedure.
- Published
- 2020
- Full Text
- View/download PDF